Azitra | 10-Q: FY2025 Q2 Revenue: USD 0

LB filings
2025.08.11 20:03
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -0.18, beating the estimate of USD -0.21.

Segment Revenue

  • Service Revenue - Related Party: $0 for the three months ended June 30, 2025, compared to $7,500 for the same period in 2024, reflecting a 100% decrease due to a reduction in reimbursable development costs.

Operational Metrics

  • General and Administrative Expenses: Decreased by $79,715, or 5%, to $1,469,513 for the three months ended June 30, 2025, compared to the same period in 2024.
  • Research and Development Expenses: Increased by $283,287, or 25%, to $1,401,839 for the three months ended June 30, 2025, compared to the same period in 2024.
  • Loss from Operations: Increased by $211,072, or 8%, to $2,871,352 for the three months ended June 30, 2025, compared to the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: $5,886,798 for the six months ended June 30, 2025, compared to $5,121,955 for the same period in 2024.
  • Net Cash Used in Investing Activities: $57,973 for the six months ended June 30, 2025, compared to $155,826 for the same period in 2024.
  • Net Cash Provided by Financing Activities: $2,435,782 for the six months ended June 30, 2025, compared to $4,284,874 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to advance its lead programs, ATR-12 and ATR-04, through clinical trials, with ATR-12 in a Phase 1b clinical trial and ATR-04 expected to dose the first patient in a Phase 1⁄2 clinical trial in the third quarter of 2025.
  • Non-Core Business: The company intends to broaden its platform by selectively exploring strategic partnerships and leveraging academic partnerships to bolster its engineering platforms and expand its research and development pipeline.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.